Phase III Antibiotic Garenoxacin Will Be Out-Licensed, Schering Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough will out-license U.S. rights to the Phase III quinolone antibiotic garenoxacin due to potential conflicts of interest related to the company's primary care marketing agreement with Bayer
You may also be interested in...
Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission
Sept. 11 advisory committee meeting on antibiotic cancelled.
Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission
Sept. 11 advisory committee meeting on antibiotic cancelled.
Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date
FDA's Anti-Infective Drugs Advisory Committee will discuss Schering-Plough's antibiotic garenoxacin on Sept. 11, according to a Federal Register pre-publication announcement July 24